Search
Selected Filters
Displaying 11–20 of 256 research results
-
PYC Doses First Patient in Clinical Trial of RNA Therapy for RP11 (PRPF31 Mutations)
Eye On the Cure Research NewsThe emerging RNA therapy is designed to boost expression of the PRPF31 protein
-
Eye On the Cure Research News
The five-year grant will advance the emerging treatments toward clinical trials
-
Beacon Therapeutics to Advance XLRP, Cone-Rod Dystrophy, and Dry AMD Gene Therapies
Eye On the Cure Research NewsAn emerging XLRP gene therapy acquired from AGTC is the company’s lead clinical program
-
Coave Reports Encouraging Phase 1/2 Clinical Trial Results for PDE6B Gene Therapy
Eye On the Cure Research NewsThe company is expanding the trial to enroll younger patients with less advanced disease
-
Summary of the Eighth Annual Retinal Cell & Gene Therapy Innovation Summit 2023
Eye On the Cure Research NewsThe Retinal Cell and Gene Therapy Innovation Summit has emerged as one of the most essential events for researchers and companies developing treatments and cures for retinal degenerative diseases. In its eighth year, the Innovation Summit featured 30 presentations from retina experts from around the world with more than 300 people in attendance.
-
Atsena Receives FDA Authorization to Launch a Gene Therapy Clinical Trial for XLRS
Eye On the Cure Research NewsKnown as The Lighthouse Study, the Phase ½ trial is expected to begin in mid-2023
-
Eric Pierce Receives Proctor Medal for Outstanding Achievements in Retinal Research
Eye On the Cure Research NewsDuring his Proctor Award Lecture, Dr. Pierce reviewed encouraging clinical trial results for Editas’ CRISPR/Cas9 treatment for people with LCA10
-
Eye On the Cure Research News
Dr. Tucker is leading the development of GMP facilities for manufacturing clinical grade retinal therapies
-
Eye On the Cure Research News
Clinical trial participants with advanced vision loss from RP were able to identify fruits and vegetables
-
Eye On the Cure Research News
Most participants with advanced retinitis pigmentosa (RP) in the trial had improved navigation and/or object discrimination in reduced lighting conditions
